Our team of neuroscience specialists ran a preclinical study with NeuroScientific Biopharmaceuticals in hopes of progressing towards a human trial for Alzheimer's later this year. Using lead drug candidate EmtinB, known to stimulate the reformation of the neuronal network and restore function of damaged nerve cells, the nerve cells were successfully able to communicate again. In fact, EmtinB was able to stimulate regeneration of nerve cells by more than 300% compared to the control. This is significant in affecting synapse loss, a key contributor of cognitive impairment. Together, we are paving the way for successful therapeutic treatment options for Alzheimer's and other neurodegenerative diseases, like Multiple Slerosis, Amyotrophic Lateral Sclerosis, Parkinson's and spinal injury.